8-KOther Events

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Mar 23, 2011)

Filed March 23, 2011For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) has filed an 8-K report detailing the initiation of a civil lawsuit against the company by The University of Utah on March 22, 2011. The University claims inventorship rights by Dr. Brenda Bass, a professor at the University, concerning the Tuschl patents. These patents are central to the field of RNA interference (RNAi) therapeutics, a core focus for Alnylam. The University is seeking corrections to the inventorship of the Tuschl patents, along with unspecified damages and other relief. Alnylam Pharmaceuticals has stated that it strongly disagrees with the claims made in the lawsuit and intends to defend itself vigorously against these allegations. This lawsuit introduces a significant legal overhang and potential risk to the company's intellectual property portfolio, which underpins its drug development pipeline.

Key Highlights

  • 1Alnylam Pharmaceuticals, Inc. is facing a civil lawsuit filed by The University of Utah on March 22, 2011.
  • 2The lawsuit concerns claims of inventorship by Dr. Brenda Bass to the Tuschl patents.
  • 3The Tuschl patents are critical to the field of RNA interference (RNAi) therapeutics, a key area for Alnylam.
  • 4The University of Utah is seeking corrections to inventorship, unspecified damages, and other relief.
  • 5Alnylam Pharmaceuticals strongly disputes the claims and intends to defend itself vigorously.
  • 6This legal action poses a potential risk to Alnylam's intellectual property and drug development pipeline.

Frequently Asked Questions

The University of Utah alleges that Dr. Brenda Bass, a professor at the University, should be recognized for inventorship on the Tuschl patents, which are foundational to RNA interference (RNAi) technology. They are seeking corrections to the inventorship of these patents.

Alnylam Pharmaceuticals, Inc. strongly disagrees with the claims made by The University of Utah and has stated its intention to defend itself vigorously against the lawsuit.

This lawsuit could have significant implications for Alnylam's intellectual property portfolio, which is crucial for its RNAi-based drug development pipeline. If the University's claims are successful, it could impact Alnylam's patent rights and potentially lead to financial liabilities.

The Tuschl patents are related to the technology of RNA interference (RNAi), a mechanism for silencing gene expression. This technology is a core focus for Alnylam Pharmaceuticals in developing new therapies.